Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study

Arthritis Care and Research

Volumn 69, Issue 1, 2017, Pages 38-45

  Rúa Figueroa, Iñigo ^a   Fernández Castro, Mónica ^b   Andreu, José L ^c   Sanchez Piedra, Carlos ^d   Martínez Taboada, Víctor ^e   Olivé, Alejandro ^f   López Longo, Javier ^g   Rosas, José ^h   Galindo, María ⁱ   Calvo Alén, Jaime ^j   Fernández Nebro, Antonio ^k   Alonso, Fernando ^d   Rodríguez Lozano, Beatriz ^l   Alberto García Vadillo, Jesús ^m   Menor, Raúl ⁿ   Narváez, Francisco Javier ^o   Erausquin, Celia ^a   García Aparicio, Ángel ^p   Tomero, Eva ^m   Manrique Arija, Sara ^k   Horcada, Loreto ^q   Uriarte, Esther ^r   Gil, Susana ^s   Blanco, Ricardo ^e   López González, Ruth ^t   Boteanu, Alina ^u   Freire, Mercedes ^v   Galisteo, Carlos ^w   Rodríguez Gómez, Manuel ^x   Díez Álvarez, Elvira ^y   Pego Reigosa, José M ^z   more..

^a Doctor Negrín Hospital of Gran Canaria   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d UNIDAD DE INVESTIGACIÓN   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h Marina Baixa Hospital   (Spain)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j Department of Psychiatry   (Spain)

^k HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^l HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^m HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁿ H Jerez de la Frontera   (Spain)

^o HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^p HOSPITAL VIRGEN DE LA SALUD   (Spain)

^q Universidad Pública de Navarra   (Spain)

^r HOSPITAL DONOSTIA   (Spain)

^s Alicante General Hospital   (Spain)

^t HOSPITAL VIRGEN DE LA CONCHA   (Spain)

^u HOSPITAL RAMÓN Y CAJAL   (Spain)

^v HOSPITAL JUAN CANALEJO   (Spain)

^w Hospital Parc Tauli   (Spain)

^x Hospital Complex of Orense   (Spain)

^y Leon Hospital   (Spain)

^z Campus Universitario   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GENDER; HEART INFARCTION; HUMAN; HYPERTENSION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CARE; PREVALENCE; REGISTER; SJOEGREN SYNDROME; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; SJOGREN'S SYNDROME;

ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREVALENCE; REGISTRIES; SJOGREN'S SYNDROME;

EID: 85006001805     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23015     Document Type: Article

References (47)

1. Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:1983–9.
2. Kang JH, Lin HC. Comorbidities in patients with primary Sjögren's syndrome: a registry-based case-control study. J Rheumatol 2010;37:1188–94.
3. Frieri M, Stampfl H. Systemic lupus erythematosus and atherosclerosis: review of the literature. Autoimmun Rev 2016;15:16–21.
4. McMahon M, Skaggs B. Pathogenesis and treatment of atherosclerosis in lupus. Rheum Dis Clin North Am 2014;40:475–95.
5. Ramos-Casals M, Brito-Zeron P, Siso A, Vargas A, Ros E, Bove A, et al. High prevalence of serum metabolic alterations in primary Sjogren's syndrome: influence on clinical and immunologic expression. J Rheumatol 2007;34:754–61.
6. Gerli R, Bartoloni BE, Vaudo G, Marchesi S, Vitali C, Shoenfeld Y. Traditional cardiovascular risk factors in primary Sjogren's syndrome: role of dyslipidaemia [letter]. Rheumatology 2006;45:1580–1.
7. Juarez M, Toms TE, de Pablo P, Mitchell S, Bowman S, Nightingale P, et al, for the UK Primary Sjögren's Syndrome Registry. Cardiovascular risk factors in women with primary Sjögren's syndrome: United Kingdom Primary Sjögren's Syndrome Registry results. Arthritis Care Res (Hoboken) 2014;66:757–64.
8. Vaudo G, Bocci EB, Shoenfeld Y, Schillaci G, Wu R, Del Papa N, et al. Precocious intima-media thickening in patients with primary Sjögren's syndrome. Arthritis Rheum 2005;52:3890–7.
9. Gravani F, Papadaki I, Antypa E, Nezos A, Masselou K, Ioakeimidis D, et al. Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations. Arthritis Res Ther 2015;17:99.
10. Sabio JM, Sánchez-Berná I, Martinez-Bordonado J, Vargas-Hitos JA, Navarrete-Navarrete N, Expósito Ruíz M, et al. Prevalence of and factors associated with increased arterial stiffness in patients with primary Sjögren's syndrome. Arthritis Care Res (Hoboken) 2015;67:554–62.
11. Rúa-Figueroa I, López-Longo FJ, Calvo-Alén J, Galindo-Izquierdo M, Loza E, García de Yebenes MJ, et al, for the Grupo de trabajo en Enfermedades Autoinmunes Sistémicas de la Sociedad Española de Reumatología (EAS-SER) of the Unidad de Investigación de la Sociedad Española de Reumatología (UI-SER). National registry of patients with systemic lupus erythematosus of the Spanish Society of Rheumatology: objectives and methodology. Reumatol Clin 2014;10:17–24.
12. Fernández Castro M, Andreu JL, Sánchez-Piedra C, Martínez Taboada V, Olivé A, Rosas J, et al, for the Grupo de trabajo en Enfermedades Autoinmunes Sistémicas de la Sociedad Española de Reumatología (EAS-SER) y de la Unidad de Investigación de la Sociedad Española de Reumatología (UI-SER). Sjögren SER: national registry of the Spanish Society of Rheumatology of patients with primary Sjögren syndrome. Objectives and methodology. Reumatol Clin 2016:12:184–9.
13. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–8.
14. Hochberg MC. Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus [letter]. Arthritis Rheum 1997;40:1725.
15. Whitworth JA, and the World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983–92.
16. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160–72.
17. Rúa-Figueroa I, Richi P, López-Longo FJ, Galindo M, Calvo-Alén J, Olivé-Marqués, et al, for EAS-SER (Systemic Diseases Study Group of the Spanish Society of Rheumatology). Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences. Medicine (Baltimore) 2015;94:e267.
18. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262–9.
19. Singh AG, Singh S, Matteson EL. Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2016;55:450–60.
20. Krylova L, Isenberg D. Assessment of patients with primary Sjögren's syndrome: outcome over 10 years using the Sjögren's Syndrome Damage Index. Rheumatology (Oxford) 2010;49:1559–62.
21. Szanto A, Szodoray P, Kiss E, Kapitany A, Szegedi G, Zeher M. Clinical, serological, and genetic profiles of patients with associated Sjögren's syndrome and systemic lupus erythematosus. Hum Immunol 2006;67:924–30.
22. Pan HF, Ye DQ, Wang Q, Li WX, Zhang N, Li XP, et al. Clinical and laboratory profiles of systemic lupus erythematosus associated with Sjögren syndrome in China: a study of 542 patients. Clin Rheumatol 2008;27:339–43.
23. Malladi AS, Sack KE, Shiboski SC, Shiboski CH, Baer AN, Banushree R, et al. Primary Sjögren's syndrome as a systemic disease: a study of participants enrolled in an international Sjögren's syndrome registry. Arthritis Care Res (Hoboken) 2012;64:911–8.
24. Bernatsky S, Ramsey-Goldman R, Joseph L, Boivin JF, Costenbader KH, Urowitz MB, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis 2014;73:138–42.
25. Fernández-Nebro A, Rúa-Figueroa Í, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alén J, Olivé-Marqués A, et al, for the EAS-SER (Systemic Diseases Study Group of Spanish Society of Rheumatology). Cardiovascular events in systemic lupus erythematosus: a nationwide study in Spain from the RELESSER registry. Medicine (Baltimore) 2015;94:e1183.
26. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012;176:708–19.
27. Bengtsson C, Ohman ML, Nived O, Rantapää Dahlqvist S. Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study. Lupus 2012;21:452–9.
28. Ballocca F, D'Ascenzo F, Moretti C, Omedè P, Cerrato E, Barbero U, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol 2015;22:1435–41.
29. Bartoloni E, Baldini C, Schillaci G, Quartuccio L, Priori R, Carubbi F, et al. Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study. J Intern Med 2015;278:185–92.
30. Perez-De-Lis M, Akasbi M, Siso A, Diez-Cascon P, Brito-Zeron P, Diaz-Lagares C, et al. Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients. Lupus 2010;19:941–8.
31. Chiang CH, Liu CJ, Chen PJ, Huang CC, Hsu CY, Chan WL, et al. Primary Sjögren's syndrome and risk of ischemic stroke: a nationwide study. Clin Rheumatol 2014;33:931–7.
32. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550–7.
33. Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008;59:1814–20.
34. Mok CC, Birmingham DJ, Ho LY, Hebert LA, Rovin BH. High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2013;65:441–7.
35. Toloza SM, Uribe AG, McGwin G Jr, Alarcón GS, Fessler BJ, Bastian HM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004;50:3947–57.
36. García-Carrasco M, Ramos-Casals M, Rosas J, Pallarés L, Calvo-Alen J, Cervera R, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 2002;81:270–80.
37. Rua-Figueroa I, Arencibia-Mireles O, Elvira M, Erausquin C, Ojeda S, Francisco F, et al. Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study. Ann Rheum Dis 2010;69:1136–9.
38. Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther 2014;16:435.
39. McMahon M, Skaggs BJ, Grossman JM, Sahakian L, FitzGerald J, Wong WK, et al. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol 2014;66:130–9.
40. Lertratanakul A, Wu P, Dyer AR, Kondos G, Edmundowicz D, Carr J, et al. Risk factors in the progression of subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2014;66:1177–85.
41. Cervera R, García-Carrasco M, Font J, Ramos M, Reverter JC, Muñoz FJ, et al. Antiphospholipid antibodies in primary Sjögren's syndrome: prevalence and clinical significance in a series of 80 patients. Clin Exp Rheumatol 1997;15:361–5.
42. Rodríguez Huerta MD, Trujillo-Martín MM, Rúa-Figueroa Í, Cuellar-Pompa L, Quirós-López R, Serrano-Aguilar P, for the Spanish SLE CPG Development Group. Health lifestyle habits for patients with systemic lupus erythematosus: a systemic review. Semin Arthritis Rheum 2016;45:463–70.
43. Atzeni F, Cazzola M, Benucci M, Di Franco M, Salaffi F, Sarzi-Puttini P. Chronic widespread pain in the spectrum of rheumatological diseases. Best Pract Res Clin Rheumatol 2011;25:165–71.
44. Ostuni P, Botsios C, Sfriso P, Bertagnin A, Cozzi F, Doria A, et al. Prevalence and clinical features of fibromyalgia in systemic lupus erythematosus, systemic sclerosis and Sjögren's syndrome. Minerva Med 2002;93:203–9. In Italian.
45. Iannuccelli C, Spinelli FR, Guzzo MP, Priori R, Conti F, Ceccarelli F, et al. Fatigue and widespread pain in systemic lupus erythematosus and Sjögren's syndrome: symptoms of the inflammatory disease or associated fibromyalgia? Clin Exp Rheumatol 2012;30 Suppl 74:117–21.
46. Haliloglu S, Carlioglu A, Akdeniz D, Karaaslan Y, Kosar A. Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity. Rheumatol Int 2014;34:1275–80.
47. Torrente-Segarra V, Salman-Monte TC, Rúa-Figueroa Í, Pérez-Vicente S, López-Longo FJ, Galindo-Izquierdo M, et al, for the RELESSER Study Group of the Spanish Society of Rheumatology (SER) and the Study Group of Systemic Autoimmune Diseases of the SER (EAS-SER). Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus. Clin Exp Rheumatol 2016;34 (Suppl 96):S40–7.